ReviewClinical immunology (Orlando, Fla.)2015
The gut microbiota and Type 1 Diabetes.
Review in Clinical immunology (Orlando, Fla.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 4 syntheses or guidelines pooled it, 168 citations in OpenAlex.
- Gut microbiome and blood glucose control in type 1 diabetes: a systematic review.Frontiers in endocrinology · 2023Pooled it
- Gut Microbiota Profile in Patients with Type 1 Diabetes Based on 16S rRNA Gene Sequencing: A Systematic Review.Disease markers · 2020Pooled it
- Ocular Microbiota and Intraocular Inflammation.Frontiers in immunology · 2020Pooled it
- Risk of Type 1 Diabetes in the Offspring Born through Elective or Non-elective Caesarean Section in Comparison to Vaginal Delivery: a Meta-Analysis of Observational Studies.Current diabetes reports · 2019Pooled it
- Repeated faecal microbiota transplantation for individuals with type 1 diabetes and gastroenteropathy.Diabetologia · 2025Trial
- Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota.The ISME journal · 2018Trial
- Effects ofBMJ open · 2017Trial
- Biochemistry of Human Gut Microbiota: Related Diseases and Dietary Interactions.Molecules (Basel, Switzerland) · 2026Review
- Exploring gut microbiome alterations and hormonal imbalances in polycystic ovary syndrome: insights from a comparative study.Journal of ovarian research · 2026Article
- Early-life gut microbiome development and its potential long-term impact on health outcomes.Microbiome research reports · 2025Review
- Targeting the TLR4 axis with microbiota-oriented interventions and innovations in diabetes therapy: a narrative review.Frontiers in immunology · 2025Review
- A 15-day pilot biodiversity intervention with horses in a farm system leads to gut microbiome rewilding in 10 urban Italian children.One health (Amsterdam, Netherlands) · 2024Article
- Unraveling the Role of the Human Gut Microbiome in Health and Diseases.Microorganisms · 2024Review
- Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches.Pharmacology & therapeutics · 2024Review
- Univariable and multivariable Mendelian randomization study identified the key role of gut microbiota in immunotherapeutic toxicity.European journal of medical research · 2024Article
- Review
- A dynamic atlas of immunocyte migration from the gut.Science immunology · 2024Article
- The Bern Birth Cohort (BeBiCo) to study the development of the infant intestinal microbiota in a high-resource setting in Switzerland: rationale, design, and methods.BMC pediatrics · 2023Article
- The Gut-Brain Axis in Autoimmune Diseases: Emerging Insights and Therapeutic Implications.Cureus · 2023Review
- Infant gut microbiome composition correlated with type 1 diabetes acquisition in the general population: the ABIS study.Diabetologia · 2023Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Type 1 Diabetes (T1D) is a multifactorial, immune-mediated disease, which is characterized by the progressive destruction of autologous insulin-producing beta cells in the pancreas. The risk of developing T1D is determined by genetic, epigenetic and environmental factors. In the past few decades there has been a continuous rise in the incidence of T1D, which cannot be explained by genetic factors alone. Changes in our lifestyle that include diet, hygiene, and antibiotic usage have already been suggested to be causal factors for this rising T1D incidence. Only recently have microbiota, which are affected by all these factors, been recognized as key environmental factors affecting T1D development. In this review we will summarize current knowledge on the impact of gut microbiota on T1D development and give an outlook on the potential to design new microbiota-based therapies in the prevention and treatment of T1D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.